Radioimmunoassay (RIA) is an in-vitro assay technique that is used to measure the concentration of antigens in blood. RIA encompasses the separation of protein from a mixture by using the specificity of antibody- antigen binding and their quantitation by using radioactivity. The method is hypersensitive and can quantify tiny amounts of hormone or drug level with the help of antibodies.

Radioimmunoassay is used owing to its high sensitivity, which can analyze nanomolar and picomolar concentrations of hormones in biological fluids. RIA has become one of the major tools in various clinical laboratories for diagnostic procedures, such as assessing the plasma levels of most of the hormones, identifying the presence of certain abused drugs, evaluating the presence of hepatitis B surface antigen in donated blood, and others. This technique is also used for the early detection of cancer, treatment of peptic ulcers, research with neurotransmitters, detection of infections, and identification of allergens in food and house dust, and so on.

The increasing usage of RIA in pharmaceutical industries, research labs, and contract research organizations (CROs) has led to an increased demand of products that are based on this technique. Furthermore, the rising need for quality and error-free results to ensure patient satisfaction has resulted in research labs and diagnostic centers to opt for high-throughput and automated procedures. This is also one of the major factors that have resulted in the growth of the RIA market to a large extent.

The global radioimmunoassay market was valued at $345.2 Million in 2014 and is expected to reach $428.4 Million in 2020 at a CAGR of 3.5% from 2015-2020.

There are two types of radioimmunoassay, which serve different functions for clinical diagnostics and research purposes. These types have been classified into reagents & kits and analyzers. In 2014, the reagents & kits segment contributed the largest share of 82.9% to the global radioimmunoassay market.

The various application areas of RIA are infectious disease testing, endocrine testing, allergy testing, oncology testing, toxicology testing, and autoimmune disease testing. Out of all the application segments, oncology testing is the largest application segment, and is expected to hold the major market share in the near future. The major reason behind this is the growth in the oncology market due to various factors, such as the increasing incidence rate of cancer, growth in aging population, urbanization with heavy pollution, and others. The research segment contributed the largest share to the global radioimmunoassay market in 2014. This segment was valued at $227.8 Million in 2014, and is projected to grow at a CAGR of 3.7% during the forecast period from 2015 to 2020.

Based on this market’s end users, the global radioimmunoassay market has been segmented into hospitals (hospital-based laboratories/hospital-attached laboratories), academics, pharmaceutical industry and CROs, clinical laboratories, and others, which include physician offices, patient self-testing centers, blood banks, home health agencies, nursing homes, and ambulatory surgical centers.

The global radioimmunoassay market has been categorized into major geographical regions, including Europe, North America, Asia, and the Rest of the world. Europe is the most dominant region in the global radioimmunoassay market, and contributed a share of 35.1% in 2014; the market in this region was valued at $121.5 Million in the same year.

This report categorizes the global market on the basis of type, application, end user, and region.

Market Segmentation, by Type:

Based on type, the global radioimmunoassay market is segmented into reagents & kits and analyzers.

Market Segmentation, by Application:

Based on application, the global radioimmunoassay market is classified into clinical diagnostics and research.

Market Segmentation, by End User:

Based on end-user, the market is segmented into hospitals, pharmaceuticals industry &CRO, academics, and clinical diagnostic laboratories, and others.

Market Segmentation, by Region:

The regional analysis covers North America, Europe, Asia-Pacific, and RoW.

Customization Options:

A company’s specific needs can be met by the customization. Customize to get a comprehensive summary of the industry standards and a detailed analysis of the following parameters: Product Analysis, Brand/Product Perception Matrix, Porters Five Force’s Analysis, Regulatory Frame Work, and Competitive Intelligence.

This report on the global radioimmunoassay market is analysed and segmented on the basis of type, application, end user, and region. It analyzes the competitive developments, such as alliance, joint venture, and merger & acquisition, in the global radioimmunoassay market. This market is also analyzed with an explicit focus on the high-growth applications and fastest-growing market segments.

The technique of radioimmunoassay (RIA) is advanced and sensitive enough to find small molecules in the blood, and is therefore used for research purposes and diagnosis of diseases, such as cancer. This technique is also implemented by organizations and research labs for specific research purposes that use animal or human serum. The new range of immunoassay kits and analyzers provide remedies for autoimmune diseases, such as diabetes. These are widely used in the process of drug discovery and screening in blood banks.

Radioimmunoassay (RIA) is one of the pivotal and traditional methods used for the testing of endocrinological disorders. RIA also has a prominent usage in the field of neurodegenerative disorders. Despite its high precision, robust nature, and impeccable sensitivity, the global radioimmunoassay market has been witnessing a slow growth, in terms of market value and kit volume. This can be attributed to the paradigm shift in the adoption of alternatives, such as ELISA, chemiluminescence assay, immunofluorescence assay, other non-radio techniques, and lack of automation.

Handling of RIA kits and tracers require special license, which in itself constitute to be a complicated process. Stringent regulatory approvals are required to set up laboratories to conduct RIA procedures. Therefore, skilled and expert professionals are required to be hired to perform RIA tests. As a result of this, the global radioimmunoassay market has been witnessing a slow growth rate.

In Europe, many clinical laboratories are adopting measures to remove RIA tests off their shelf; ELISA has been instrumental in taking over the RIA tests. European Greens is significant in the maintenance of environmental responsibility across different regions. The utilization of radioactive substances in RIA procedures poses a threat to environment and human health. Thus, the present scenario has negatively impacted the usage of RIA tests in Europe due to the conscious effort from the European Greens to replace this. Despite the aforementioned dynamics, Europe captures a major market share in the global RIA market. Majority of the RIA manufacturers are based out of Europe, thereby claiming a strong footprint in Europe.

Siemens recently discontinued the production of their RIA kits, which left its customers with the option of seeking replacement products. This event has resulted in an opportunity for other RIA players to achieve growth in the global RIA market. Companies, such as IBL International (A Tecan Company) (U.S.), DIAsource Immunoassays SA (Italy), DRG International, Inc. (U.S.), and MP Biomedicals, LLC (U.S.), can leverage upon this opportunity to enhance their profits.

The global radioimmunoassay market was dominated by Europe in 2014, followed by North America, Asia, and the Rest of the World (RoW). Europe is expected to continue to lead the market in the coming years, followed by North America. Over the years, there has been a significant growth in the utilization of the radioimmunoassay technique in Europe owing to the advancements in medical research, clinical trials, and pharmaceutical industries. Over the next five years, the growth in the Asian Radioimmunoassay (RIA) Market is expected to be centred in China, India, and Japan. The growth in this region is anticipated to be mainly driven by factors, such as the increasing number of tests performed, rising adoption rate of advanced techniques, and rising intrinsic demand from China and India due to their respective large population base. The market in Asia is projected to grow at the highest CAGR of 4.5% during the forecast period from 2015 to 2020.

The global radioimmunoassay market was valued at $345.2 Million in 2014. The European radioimmunoassay (RIA) market contributed the largest share to the global market, and was valued at $121.5 Million in 2014. It is projected to grow at a CAGR of 3.9% during the forecast period from 2015 to 2020. North America was the second-largest market, and the market in this region is expected to be driven by the gradually increasing awareness, investments by government & non-government organizations, and establishment of research centres.